Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals: strong revenue growth and positive discussions with BARDA and potential partners are countered by regulatory and operational risks, including NASDAQ compliance concerns and workforce reductions. The Q&A reveals management's cautious optimism but also highlights uncertainties, especially regarding timelines and specifics on the COVID program. These factors, along with a potential reverse stock split, suggest a neutral short-term stock price movement, with no clear catalyst for significant gains or losses.
Key Financial Performance
Revenue $20.9 million (up from $2.2 million), a year-over-year increase of 850%. Revenue in Q1 2025 was primarily from the BARDA contract awarded in June 2024, while revenue in Q1 2024 was from a different BARDA contract awarded in January 2024.
Cash Position $41.9 million in cash, cash equivalents, and investments. This reflects the company's efforts to streamline costs and align its workforce with business needs, which were necessary to maximize future opportunities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
COVID-19 Vaccine Trial: The stop work order on the 10,000 participant portion of the Project NextGen Phase 2b COVID-19 vaccine trial has been lifted, allowing patient screening and dosing to begin in Q2 2025.
Norovirus Vaccine Trial: Enrollment in the Phase 1 trial comparing second generation constructs with first generation constructs has been completed, with top-line data expected in mid-2025.
Avian Flu Vaccine Development: Preclinical studies show a new avian flu vaccine candidate was 100% protective against death in ferrets, with plans to present data at a scientific conference.
BARDA Contract: Vaxart's contract with BARDA provides up to $460.7 million for the Phase 2b study, contributing to revenue growth.
Revenue Growth: Revenue for Q1 2025 was $20.9 million, a significant increase from $2.2 million in Q1 2024, primarily due to the BARDA contract.
Cost Rationalization: Vaxart has implemented workforce reductions to streamline costs and maximize future opportunities.
Cash Position: Vaxart ended Q1 2025 with $41.9 million in cash, cash equivalents, and investments, expecting a cash runway into Q1 2026.
CFO Transition: Phil Lee resigned as CFO, with Jeroen Grasman appointed as the new CFO, bringing over 20 years of biotech experience.
Reverse Stock Split Proposal: A reverse stock split is proposed to maintain NASDAQ listing, as the current stock price does not meet the $1 minimum bid requirement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: Uncertainty inherent in the clinical development and regulatory process could materially affect actual results compared to forward-looking statements.
Funding Risks: The company is actively seeking strategic partnerships and non-dilutive funding options to extend its cash runway, which is currently projected to last until Q1 2026.
Operational Risks: Recent workforce reductions were necessary to streamline costs and maximize future opportunities, indicating potential challenges in maintaining operational efficiency.
Market Risks: The company faces risks related to maintaining its NASDAQ listing, including the potential for delisting if it does not regain compliance with the $1 minimum bid price requirement.
Competitive Pressures: The company is under pressure to demonstrate the efficacy of its vaccine candidates in a competitive biotech environment, particularly with the upcoming data readout for its norovirus vaccine.
Public Health Risks: The ongoing threat of COVID-19 and avian flu outbreaks presents both a challenge and an opportunity for the company, necessitating effective vaccine development.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Project NextGen Phase 2b COVID-19 Vaccine Trial: The stop work order on the 10,000 participant portion of the trial has been lifted, and patient screening is actively underway with dosing expected to begin in Q2 2025.
BARDA Contract: Vaxart operates under a contract with BARDA providing up to $460.7 million for the Phase 2b study.
Norovirus Vaccine Program: Enrollment in the Phase 1 trial comparing second generation constructs with first generation constructs has been completed, with top-line data expected in mid-2025.
Avian Flu Vaccine Development: Preclinical studies show a new avian flu vaccine candidate was 100% protective against death in ferrets, with plans to present data at scientific forums.
Cost Rationalization: Vaxart has implemented workforce reductions to streamline costs and maximize future opportunities.
Revenue Expectations: Revenue for Q1 2025 was $20.9 million, up from $2.2 million in Q1 2024, primarily from the BARDA contract.
Cash Runway: Vaxart expects its cash runway to extend into Q1 2026.
Future Clinical Trials: If Phase 1 results for the norovirus vaccine are positive, a Phase 2b study could begin in H2 2025, followed by a potential Phase 3 trial in 2026.
Reverse Stock Split: A reverse stock split is being considered to maintain NASDAQ listing, with a focus on regaining compliance by June 30.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Reverse Stock Split Proposal: Vaxart is proposing a reverse stock split to maintain compliance with NASDAQ's $1 minimum bid price requirement. This measure is considered necessary to avoid delisting, which could adversely affect the company's value and liquidity.
Current Cash Position: Vaxart ended Q1 2025 with cash, cash equivalents, and investments of $41.9 million, with plans to extend cash runway into Q1 2026.
Funding Strategy: The company is actively pursuing strategic partnerships and non-dilutive funding options to support its clinical and regulatory milestones.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the gating factors to start patient dosing for the COVID-19 program?
A:The stop work order was lifted, and we had a conference call with BARDA to discuss the next steps, including patient screening. We hope to get the green light to start dosing soon.
Q:How fast do you think you can complete enrollment of the 10,000 participants in the Phase 2b study?
A:Approximately five to six months, but this is an estimate that may adjust based on initial screening results.
Q:What does a positive Phase 1 result look like for the norovirus program?
A:Success would mean that the new constructs are trending better than the old constructs on key immunogenicity endpoints.
Q:Have there been any learnings from the sentinel cohort that are informative to the COVID discussions?
A:The conversations with BARDA have been productive, and we incorporate learnings from enrollment and shipping logistics.
Q:What items were looked at in the recent DSMB review for the norovirus trial?
A:The review focused on safety to ensure a clean safety profile to move forward with the protocol.
Q:What is the impact of the stop work order on your expected timeline to complete the COVID study?
A:The stop work order had a minor impact, but we are reactivating sites and expect to begin dosing soon.
Q:Are there any active conversations regarding potential partnerships for the norovirus program?
A:Yes, we are having discussions with a range of companies, and interest is expected to accelerate after top-line results are released.
Q:Can you elaborate on your conversations with BARDA and HHS regarding the COVID program?
A:Conversations have been productive, but details are confidential due to contractual obligations.
Q:Why was the decision made to use a lower dose for the Phase I clinical trial of the norovirus vaccine?
A:The lower dose was chosen based on safety and immunogenicity data from previous trials, and we are conducting a dose-ranging study.
Q:What goes into determining the ratio of the reverse stock split, if approved?
A:The board intends to select a ratio that is high enough to cure the NASDAQ deficiency but small enough to minimize dilution.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specifics of the sentinel cohort's data and its implications for the COVID program, stating they are blinded and cannot provide further details. Additionally, they did not clarify the exact timeline for the COVID study's completion after the stop work order.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
HHS
biotech
candidate generation
candidate study
comparator KP
concern spread
contact
cow
decision
development vaccine
efficacy immunogenicity
finance
flu outbreak
generation norovirus
head
healthcare
individual
influenza
label
lifting stop
measure
mid
norovirus vaccine
order portion
partner
peer
person
pharmaceutical product
portion study
poultry
reason
release today
risk infection
safety efficacy
stop work
study result
study trial
week
work order
VXRT Transcript
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call highlights a significant revenue increase and extended cash runway, which are positive. However, the dependency on partnerships for advancing the norovirus program and the BARDA stop work order pose risks. The Q&A session revealed uncertainty about independent trial initiation for the norovirus program, reflecting potential challenges. These mixed signals suggest a neutral sentiment, with positive financials balanced by strategic uncertainties.
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed outlook. Positive aspects include revenue growth, a strong cash runway, and promising vaccine developments. However, workforce reductions, dependency on external funding for trials, and uncertainties in partnerships and trial progress are concerning. The Q&A highlighted management's lack of clarity on key issues, such as the COVID-19 trial's stop work order, which raises uncertainty. Despite potential catalysts like the avian flu vaccine, uncertainties and financial challenges balance out the positives, leading to a neutral sentiment.
Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call summary presents mixed signals: strong revenue growth and positive discussions with BARDA and potential partners are countered by regulatory and operational risks, including NASDAQ compliance concerns and workforce reductions. The Q&A reveals management's cautious optimism but also highlights uncertainties, especially regarding timelines and specifics on the COVID program. These factors, along with a potential reverse stock split, suggest a neutral short-term stock price movement, with no clear catalyst for significant gains or losses.
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript
Unknown3-24
The earnings call highlights significant challenges, including a stop work order from BARDA and workforce reductions, indicating financial and operational strain. Despite a positive EPS surprise, the lack of clear guidance on future product efficacy and management's vague responses during the Q&A add to uncertainties. The increase in revenue is overshadowed by these issues, and future funding strategies are speculative. The overall sentiment leans negative due to regulatory and competitive pressures, potential supply chain issues, and the need for strategic funding to maintain operations.
VXRT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
